Synthesis and structure-activity relationship studies of 2,3-dihydroimidazo[2,1-a]isoquinoline analogs as antitumor agents

Archives of Pharmacal Research

Volumn 20, Issue 2, 1997, Pages 138-143

  Cheon, Seung Hoon ^a   Park, Joon Suck ^a   Jeong, Seon Hee ^a   Chung, Byung Ho ^a   Choi, Bo Gil ^a   Cho, Won Jea ^a   Kang, Boo Hyon ^b   Lee, Chong Ock ^b  

^a Chonnam National University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Antitumor; Imidazoisoquinolines; SDZ 62 434

Indexed keywords

EID: 3342897211     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02974000     Document Type: Article

References (19)

1. Bazill, G. W. and Dexter, T. M., Role of endocytosis in the action of ether lipids on WEHI-3B, HL6O and FDCP-Mix A4 Cells, Cancer Res., 50, 7505-7512 (1990).
2. Berdel, W. E., Bausert, W. R., Weltzien H. U., Modolell M. L., Widmann, K. H. and Munder, P. G., The influence of alkyl lysophospholipids and alkyl lysophospholipid-activated macrophages on the development of metastasis of 3-lewis lung carcinoma, Eur. J. Cancer, 16, 1199-1204 (1980).
3. Berdel, W. E. and Munder, P. G., Antitumor Analogs of PAF, In Snyder, F. (Ed). Platelet-activating factor and related lipid mediators. Plenum Press, New York, 1987, pp. 449-467.
4. Berdel, W. E., Membrane-interactive lipids as experimental anticancer drugs. Br. J. Cancer, 64, 208-211 (1991).
5. Botteghi, C., Chelucci, G. and Marchetti, M., Syn. Commu., 12, 25-33 (1982).
6. Dive, C., Watson, J. V. and Workman, P., Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL6O human promyelocytic leukemia cells. Cancer Res., 51, 799-806 (1990).
7. Houlihan, W. J. and Parrino, V. A., Directed lithiation of 2-phenyl-and 2-(o-methylphenyl)imidazoline. J. Org. Chem., 47, 5177-5180 (1982).
8. Houlihan, W. J., Cheon, S. H., Parrino, V. A., Handley, D. A. and Larson, D. A., Structural modification of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinoline platelet activating factor receptor antagonists. J. Med. Chem., 36, 3098-3102 (1993).
9. Houlihan, W. J., Munder, P. G., Handley, D. A., Cheon, S. H. and Parrino, V. A., Antitumor activity of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinolines. J. Med. Chem., 38, 234-240 (1995a).
10. Houlihan, W. J., Lohmeyer, M., Workman, P. and Cheon, S. H., Phospholipid antitumor agents. Med. Res. Rev., 15, 157-223 (1995b).
11. Houlihan, W. J., Munder, P. G., Handley, D. A. and Nemecek, G. A., Priclinical pharmacology and possible mechanism of action of the novel antitumor agent 5-(4′-piperidinomethylphenyl)-2,3-dihydroimidazo[2,1-a]isoquinoline. Arzneim.-Forsch./Drug Res., 45(II), 1133-1137 (1995c).
12. Modest, E. J., Berens, M. E., Piantadosi, C. and Noseda, A., Pharmacological effects and anticancer activity of new ether phospholipid analogs, In Kabara J. J. (Ed). The Pharmacological effect of lipids III, Role of Lipids in Cancer Research. The American Oil Chemists' Society, Champaign, IL, 1989, pp. 330-337.
13. Munder, P. G. and Westphal, O., Antitumoral and other biomedical activities of synthetic ether lysophospholipids. In Waksman, B. H. (Ed). 1939-1989: Fifty Years Progress in Allergy. Karger, New York, 1990, pp. 206-235.
14. Noller, C. R. Org. Synth. Coll. Vol. II, 586-588 (1943).
15. Noseda, A., Godwin, P. L. and Modest, E. J., Effects of antineoplastic ether lipids on model and biological membranes. Biochim. Biophys. Acta, 945, 92-100 (1988).
16. Poindexter, G. S., J. Org. Chem., 47, 3787-3788 (1982).
17. 2+ signaling by antitumor ether lipid analogues. Cancer Res., 50, 4458-4463 (1990).
18. Uberall, F., Oberhuber, H., Maly, K., Zaknun J., Demuth, L. and Grunicke, H. H., Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res., 51, 807-812 (1991).
19. Workman, P., Antitumor ether lipids: endocytosis as a determination of cellular sensitivity. Cancer Cells, 3, 315-317 (1991).